TVAX Biomedical is a pioneering company based in Lenexa, KS, dedicated to developing a groundbreaking cancer treatment that has the potential to revolutionize the field. Their unique personalized killer T cell therapy, known as TVAX Immunotherapy, harnesses the natural ability of T cells to effectively target and destroy cancer cells, offering improved clinical outcomes and reduced toxicity compared to traditional treatments like radiation and chemotherapy.
What sets TVAX apart from other cancer immunotherapy companies is their use of ex vivo-activated cancer antigen-specific killer T cells as the active agent in their treatment. Their lead candidate, TVI-Brain-1, is currently undergoing evaluation for the treatment of glioblastoma, a type of brain cancer. With Fast Track Designation from the FDA and a significant grant from the FDA office of orphan products, TVAX is poised to make significant strides in the fight against cancer.
Generated from the website